Literature DB >> 9873213

Idiopathic calcium nephrolithiasis.

M Marangella1, C Vitale, C Bagnis, M Bruno, A Ramello.   

Abstract

Calcium nephrolithiasis (CaNL) accounts for more than 70% of all renal stones, and its prevalence has increased in the last decades. Under this definition are included patients passing stones, composed of calcium oxalates and/or calcium phosphates. Current views of the pathogenesis of CaNL are based on the role of metabolic abnormalities which concur to render urines more conducive to crystallization. Therefore, the diagnostic approach is aimed at detecting these abnormalities, and the medical treatment assumes that a decrease in the risk of lithogenesis will result in remission or improvement of recurrences. The workup of the patients with CaNL begins with the analysis of passed stones and X-ray, sonography or other imaging techniques. Eligible patients, that is, both recurrent active stone formers and single-stone formers with individual risk factors, are considered for a metabolic evaluation, by which a number of blood and urine parameters are measured and others calculated. These include estimates of urine state of saturation with calcium and uric acid salts, net gastrointestinal alkali absorption, renal threshold of phosphate and other renal clearances and net acid and total nitrogen excretions. Basically, this screening is informative on renal function, metabolic abnormalities and their pathophysiology, risk of stone formation and dietary habits. During treatment it gives information about patient compliance and adverse effects of therapy. The cost of a comprehensive screening in Piedmont is 192,000 ITL (100 Euro) and rises to 300,000 ITL (154 Euro) if hormones and hydroxyproline are measured. In individual patients second- and third-level studies are performed, in order to detect systemic diseases which account for about 20% of CaNL in our series. Cost-to-benefit analysis has shown that the medical procedures for CaNL yield considerable saving in terms of difference between expenditure for drugs and testing and reduction of stone events. However, the current workup cannot be considered exhaustive, because misleading events may hamper the relation between laboratory findings and clinical outcome, and factors other than urine composition have appeared on the scenario of nephrolithiasis. These represent our challenge for the third millennium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9873213     DOI: 10.1159/000046297

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

1.  Protective impact of resveratrol in experimental rat model of hyperoxaluria.

Authors:  Taylan Oksay; Sedat Yunusoğlu; Mustafa Calapoğlu; I Aydın Candan; İbrahim Onaran; Osman Ergün; Alper Özorak
Journal:  Int Urol Nephrol       Date:  2017-02-09       Impact factor: 2.370

2.  Biochemical evaluation in renal stone disease.

Authors:  Corrado Vitale; Emanuele Croppi; Martino Marangella
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

3.  Use of drugs for nephrolithiasis.

Authors:  Martino Marangella; Corrado Vitale; Cristiana Bagnis; Michele Petrarulo; Alberto Tricerri
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

4.  Bone and metabolic markers in women with recurrent calcium stones.

Authors:  Miguel Angel Arrabal-Polo; Miguel Arrabal-Martin; Salvador Arias-Santiago
Journal:  Korean J Urol       Date:  2013-03-15

5.  The relationship between insulin, insulin resistance, parathyroid hormone, cortisol, testosterone, and thyroid function tests in the presence of nephrolithiasis: a comprehensive analysis.

Authors:  Baris Afsar; Halit Karaca
Journal:  Cent European J Urol       Date:  2014-04-17

6.  Aggregation of Calcium Phosphate and Oxalate Phases in the Formation of Renal Stones.

Authors:  Baoquan Xie; Timothy J Halter; Ballav M Borah; George H Nancollas
Journal:  Cryst Growth Des       Date:  2014-11-12       Impact factor: 4.076

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.